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http://dxObjective: Systemic tacrolimus therapy has been shown to protect against lung ischemia-reperfusion injury in
animal models. We sought to investigate on a functional and cellular level if inhaled nanoparticle tacrolimus
administered to the donor lung before procurement could similarly attenuate ischemia-reperfusion injury after
lung transplant.
Methods: An isogenic orthotopic rat model of single left lung transplant was used. Donor animals were pre-
treated with inhaled tacrolimus (treatment group) or inhaled lactose (controls) before lung procurement.
Lung grafts were subjected to 3 hours of cold ischemia followed by 4 hours of reperfusion after graft implan-
tation. Recipient animal arterial blood gas measurement and isograft wet to dry weight ratios were obtained.
Macrophage, neutrophil, and T-cell accumulation and activation in lung isografts, including gd T-cell, T-helper,
and cytotoxic T-cell subtypes were analyzed by flow cytometry. Tacrolimus levels were measured in the lung
isograft using liquid chromatography/mass spectrometry. Isograft cytokine levels were measured with commer-
cial enzyme-linked immunosorbent assay and microbead array kits.
Results: Oxygenation in treatment group animals was significantly higher than in controls. The presence of
macrophages, neutrophils, and all T-cell subtypes in the isografts as well as isograft levels of inflammatory
cytokines were all less in the treatment group versus controls, although no single variable achieved statistical
significance.
Conclusions: Inhaled nanoparticle tacrolimus treatment of lung donors is associated with an attenuation of
ischemia-reperfusion injury on a functional and cellular level in lung transplant. (J Thorac Cardiovasc Surg
2013;146:1213-9)T
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SDonor allograft ischemia-reperfusion injury (IRI) is an
important source of morbidity and mortality after lung
transplant.1 IRI is thought to play a central role in the
development of primary graft dysfunction, an important
source of morbidity and mortality in the first year
following lung transplant affecting up to 10% to 25%
of all lung transplant recipients.1 Furthermore a retrospec-
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Eidentified an increased risk of developing chronic rejection
(bronchiolitis obliterans syndrome) in patients who experi-
enced IRI.2
It has been shown that tacrolimus is able to attenuate
IRI. It has been associated with an attenuation of IRI
through decreased free radical production, inhibition of
calcium-dependent pathways, and inhibition of nuclear
factor kB.3 In a rat lung warm ischemia reperfusion
model, pretreatment with systemically administered tacro-
limus was associated with a decrease in IRI via a reduc-
tion in proinflammatory cytokine expression and
neutrophil accumulation in the lung tissue.4 The potential
downside of systemic treatment of the donor with tacroli-
mus before organ procurement includes nephrotoxicity at
the doses required to achieve adequate tissue levels in
the lung. However, the lung affords a unique route of
administration via inhalation therapy. Recently, an inhaled
nanoparticle formulation of tacrolimus was characterized
in terms of its pharmacokinetics to provide high lung
and low systemic tacrolimus levels, theoretically reducing
the risk of nephrotoxicity of tacrolimus therapy.5 We
sought to determine if pretreatment of donor animals
with this novel inhaled preparation of tacrolimus before
organ procurement and subsequent transplantation into a
recipient animal could attenuate IRI by functional and
cellular analysis.diovascular Surgery c Volume 146, Number 5 1213
Abbreviations and Acronyms
CD ¼ clusters of differentiation
IRI ¼ ischemia-reperfusion injury
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Animals
Isogenic, orthotopic, left lung transplants were performed using male
inbred Fischer rats (Charles River, Wilmington, Mass). The Institutional
Animal Care and Use Committee of The University of Texas Health Sci-
ence Center at San Antonio approved this animal research protocol (Insti-
tutional Animal Care and Use Committee protocol No. 11052x) and all
animals received humane treatment in accordance with the Principles of
Laboratory Animal Care formulated by the National Society for Medical
Research and the Guide for the Care and Use of Laboratory Animals pre-
pared by the National Academy of Sciences and published by the National
Institutes of Health.
Inhalation
Nanoparticle tacrolimus was prepared by The University of Texas Col-
lege of Pharmacy, Austin, Tex. Nebulized nanoparticle tacrolimus con-
sisted of 12.8 mg nanoparticle tacrolimus mixture (6.4 mg nanoparticle
tacrolimusþ 6.4 mg lactose) dispersed in 6 mL normal saline by sonication
for 3 minutes. Awake, spontaneously breathing donor animals in the treat-
ment group (n ¼ 6) received a 1-time dose of inhaled nebulized nanopar-
ticle tacrolimus before graft procurement via a nose-only dosing
chamber (AeroNeb Pro nebulizer; Aerogen, Galway, Ireland). Lactose so-
lution was prepared by mixing 6.4 mg lactose powder with 6 mL normal
saline by agitation for 3 minutes. Control animals (n ¼ 6) received nebu-
lized lactose once before lung harvest in a manner identical to that
described for treatment animals. The lungs from the donor animals in the
treatment and control group underwent procurement within 1 hour of
administration of the nanoparticle tacrolimus or nebulized lactulose.
Donor Organ Procurement
Donor rats were anesthetized using 3% to 5% inhaled isoflurane (Halo-
carbon, River Edge, NJ) admixed with oxygen via tracheostomy on a small
animal ventilator (Harvard Apparatus, Holliston, Mass) with a tidal volume
of 10 mL/kg and a respiratory rate of 60 to 80 bpm with positive end expi-
ratory pressure of 2 cm water. Heparin 1000 units/kg (APP Pharmaceuti-
cals, Schaumburg, Ill) was administered intravenously through the penile
vein or hepatic bed. Laparosternomy incision was performed. Lung preser-
vation was performed with 20 mL Perfedex solution (Xvivo, G€oteborg,
Sweden) at 4C and 20 cm water perfusion pressure delivered via the pul-
monary artery. The tracheawas clamped after insufflation of the lung to 3 to
4 cm water pressure. After transfer of the excised heart-lung block to a
frozen operating stage, the left pulmonary vein, artery, and left main bron-
chus were mounted with cuffs fashioned from 14-Ga angiocatheters (Bec-
ton Dickinson, Sandy, Utah). Lungs were preserved for a 3-hour period of
cold ischemia in an inflated state submerged in Perfedex solution at 4C af-
ter which they were transplanted into recipient animals.
Transplantation
Orthotopic left lung transplantation with modified cuff technique was
performed as described by Mizuta and colleagues.6 Recipient rats were
anesthetized as described above for donor animals via oro-tracheal intuba-
tion with a 14-Ga angiocatheter. Left lateral thoracotomy was performed
and hilar structures clamped using microaneurysm clips (Yasargil; Aescu-
lap, Center Valley, Pa). The donor pulmonary artery, vein, and bronchus
were anastomosed to respective structures of the recipient using 6-0 silk
ties. The recipient procedure was timed to achieve a total ischemic time1214 The Journal of Thoracic and Cardiovascular Surof 3 hours in the donor lung. Thoracotomy incisions were closed using
3-0 Ethibond suture (Ethicon Inc, Somerville, NJ). The recipient animal
was extubated after demonstrating spontaneous breathing and was recov-
ered from anesthesia in a warm chamber attached to a 100% oxygen line.
Experimental Endpoint and Sample Collection
Recipient animals were allowed to recover from anesthesia and resume
full activity followed by euthanasia timed to achieve 4 hours of reperfusion
of the transplanted isograft.
At euthanasia, recipient animals were anesthetized and ventilated at set-
tings as described above via tracheostomy. Laparosternomy incision was
performed. Arterial blood gas analysis was performed by ascending aortic
puncture after clamping the right lung hilum and hyperventilation (at 100
bpm) for 5 minutes. All rats were ventilated with inspired oxygen fraction
of 100% oxygen at the time of the aortic puncture. Bronchoalveolar lavage
was performed using 5 mL phosphate buffered saline. The left lung was
flushed via the pulmonary artery using normal saline (Braun Medical
Inc, Irvine, Calif) at 4C before left lung isograft excision. Samples for
flow cytometry assay were collected and the segment employed for wet
to dry ratio was weighed immediately. The remaining segments of lung tis-
sue designated for measurement of cytokines and tacrolimus levels were
frozen in liquid nitrogen. All samples for cytokine and tacrolimus levels
were stored in a –80C freezer until analysis.
A group of na€ıve animals were euthanized in the same fashion as the
recipient animals to obtain baseline parameters; these animals did not
receive any treatment or underwent any procedures beside euthanasia un-
der anesthesia. On these animals the same analysis was performed and
the same samples collected as in the treatment and control group. The re-
sults for the na€ıve animals were not included, because the purpose of this
study was to show the effect of inhaled tacrolimus on the IRI compared
with the control group.
The overall studies design did not allow the personnel involved in the
experimental part and the sample collection to be blinded, but all animals
were treated in the same manner regardless of which group they belonged
to following a strict protocol that was developed before starting the exper-
iment. The cytokine analysis and the analysis of the tacrolimus levels were
performed by independent laboratories workers of which where blinded to
the study design and the collected samples.
Arterial Blood Gas
Arterial blood gas analysis was performed using an Optical ABG ma-
chine (OPTI CCA-TS analyzer; OPTI Medical Systems, Inc, Roswell,
Ga). Alveolar-arterial gradient was calculated using the arterial oxygen
tension, arterial carbon dioxide tension, and the barometric pressure ob-
tained from the arterial blood gas analysis via an online calculator
(http://www.globalrph.com/aagrad.htm).
Wet to Dry Weight Ratio
For the wet to dry ratio the lung tissue was weighed immediately after
euthanasia (wet weight) followed by drying in a humidity controlled incu-
bator (CO2 water jacketed incubator; Forma, Thermo-Scientific,
Waltham, Mass) at 37.5C. After 48 hours the lung tissue was weighed
again and the dry tissue weight obtained. The wet to dry ratio was calcu-
lated by dividing the wet weight from the dry weight.
Flow Cytometry
Left lung isograft tissue for flow cytometry analysis underwent diges-
tion with 1 mg/mL collagenase and deoxyribonuclease (Sigma-Aldrich,
St Louis, Mo) in RPMI 1640 medium (Invitrogen, Grand Island, NY) for
30 minutes, followed by filtering through a 70-mm filter to achieve a single
cell suspension. One million cells for each tested sample were transferred
to fluorescence activated cell sorting tubes after cell counting with an auto-
mated cell counter (Countess; Invitrogen, Grand Island, NY). The cellgery c November 2013
TABLE 1. Antibody panel for flow cytometry analysis
Antibodies Flurochrome Concentration Clone Source Isotype
Panel A
Anti-rat CD11b/c APC 0.2 mg/mL OX-42 BioLegend* Mouse IgG2a, k
Anti-rat CD3 FITC 0.5 mg/mL G4.18 eBiosciencey Mouse IgG3, k
Anti-rat TCR g/d PE 0.2 mg/mL V65 BioLegend Mouse IgG1, k
Anti-rat CD25 Per CP-eFluorz 710 0.2 mg/mL OX 39 eBioscience Mouse IgG1
Panel B
Anti-rat CD3 PE 0.2 mg/mL G4.18 eBioscience Mouse IgG3, k
Anti-rat CD4 FITC 0.5 mg/mL OX 35 eBioscience Mouse IgG2a
Anti-rat CD8a APC 0.2 mg/mL G28 BioLegend Mouse IgG2a, k
Anti-rat CD25 Per CP-eFluorz 710 0.2 mg/mL OX 39 eBioscience Mouse IgG1
CD, Clusters of differentiation; APC, allophycocyanin; IgG, immunoglobulin G; TCR, T-cell receptor; PE, phycoerythin; FITC, fluorescein isothiocyanate. *BioLegend, San
Diego, Calif. yeBioscience, San Diego, Calif. zPer CP-eFluor, emits at 710 nm and is excited with the blue laser (488 nm).
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(CD) molecules CD3, CD45, CD8, CD4, CD 25, gd T-cell receptor, and
CD11b antibodies. Two different panels were used (see Table 1).
Flow cytometry was performed using a LSR II flow cytometer (Becton
Dickinson, Franklin Lakes, NJ); analysis was performed by the institu-
tional core flow cytometry facility. For each sample 30,000 events were
counted. The data was analyzed using FACSDiva software (version
6.1.3; BD Biosciences, San Jose, Calif).
Tacrolimus Level
Tacrolimus levels were quantified in the isografts of treatment group an-
imals using high-performance liquid chromatography with tandem mass
spectroscopy detection in the institutionalMass SpectrometryCore Facility.
Cytokine Assay
Liquid-nitrogen frozen lung tissue (0.1-0.4 g) was thawed on ice and ho-
mogenized in 0.4 mL extraction reagent (T-PER; Thermo Fisher Scientific
Inc, Rockford, Ill) with 1 tablet/10 mL Complete Mini Protease Inhibitor
Cocktail (Roche Diagnostics, Mannheim, Germany), and supernatants
collected following centrifugation. Interleukin (IL)-1a, IL-1b, IL-2, IL-4,
IL-6, IL-10, IL-12 (p40/p70), granulocyte-macrophage colony-
stimulating-factor, interferon-g, and tumor necrosis factor-a were quanti-
fied by microbead array using a rat 10-plex panel (Invitrogen, Camarillo,
Calif) analyzed on a Flexmap 3D multiplexing platform (Luminex, Austin,
Tex). Rat IL-17 and IL-18 were quantified using rat IL-17A (eBioscience,
San Diego, Calif) and IL-18 (Invitrogen, Grand Island, NY) enzyme-linked
immunosorbent assays according to the manufacturers’ instructions.
Statistical Analysis
All animals included in the analysis had survived to the experimental
endpoints and had complete set of data for various assays.
Treatment groups (treated, control, and na€ıve) were contrasted on the
mean using analysis of variance with Tukey correction for pairwise com-
parisons. Continuously distributed outcomes were summarized with the
mean standard deviation (SD). The na€ıve group is not included in the re-
sults section and all P values represent the Tukey corrected comparison of
the treated and control groups. For certain variables, indicated in Table 1,
data were transformed using the natural log before analysis. All values
are shown in original units. All analyses were performed using R 2.14.2
(The R Foundation for Statistical Computing; www.r-project.org).
RESULTS
Cohort Characteristics and Operative Times
The mean  SD weight of the donor animals in the
treatment and control groups were 262.8  10.9 g andThe Journal of Thoracic and Car270.7  21.3 g, respectively (P ¼ .69) and of recipient an-
imals in treatment and control groups were 265.5  12.5 g
and 272.8  16.7 g, respectively (P ¼ .42). The mean time
from treatment to isograft procurement was 26.7  1.6 mi-
nutes in the treatment group versus 27.2  7.3 minutes in
the control group (P¼ .87). Total ischemia time in the treat-
ment versus control groups were 180  3.4 minutes and
184.7  8.8 minutes, respectively (P ¼ .25). The reperfu-
sion time for the treatment group was 237.2  4.1 minutes
and for controls was 235.8  6.1 minutes (P ¼ .66).
Arterial Blood Gas and Alveolar-Arterial Gradient
The mean arterial oxygen tension value obtained from
treatment group recipient animals (344.8  235.1 mm
Hg) was significantly higher than controls (61.3  21.4
mm Hg) (P ¼ .01). The mean alveolar to arterial oxygen
gradient in the treatment group was significantly less than
controls (231.8  214.2 mm Hg vs 502.8  35.8 mm Hg;
P ¼ .01).
Wet to Dry Ratio
No significant difference in wet to dry weight ratio
between treatment animals (12.5  1) and controls
(11  1.7) was noted (P ¼ .99).Flow Cytometry in Isograft Lung Tissue
CD11b/c expressing cells were divided by scatter plot
into 2 distinct cell populations based on their cell
complexity (side scatter): CD11b/c low cells represent
structurally less complex cells and are consistent with mac-
rophages/monocytes and CD11b/c high cells representing
structural more complex cells, like granulocytes that
include the neutrophil cell population (Figure 1).7
Flow cytometric analysis of the presence of inflamma-
tory/immune cell subgroups in the lung isograft tissue
showed a decrease in every measured cell type in treatment
animals versus controls as well as in total cells per gram of
lung tissue; however, none of these individual variables
achieved statistical significance (Table 2).diovascular Surgery c Volume 146, Number 5 1215
FIGURE 1. Flow cytometry scatter plot showing separation of the two
CD11b cell populations by side scatter. CD11b high cell population
(granulocytes/neutophils). CD11b low cell population ( monocytes/macro-
phages).
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The mean tacrolimus level in the lung isografts of treat-
ment group animals after 3 hours of cold ischemia and
before transplantation was 877.98  174.36 pg/mg. After
4 hours of reperfusion the tacrolimus level in the lung tissue
dropped to 34.58  6.2 pg/mg.
When the tacrolimus levels were compared with the arte-
rial oxygen tension levels, it was noted that the animals with
the highest arterial oxygen tension levels also had the high-
est level of tacrolimus in the donor lung tissue before trans-
plantation. The opposite observation was made for the
neutrophil population (CD11b/c high positive cells) found
on flow cytometry, the animals with the highest neutrophil
count in the lung tissue had the lowest tacrolimus levels.
(See Figure 2.)
Cytokine and Chemoattractant Levels
None of the isograft tissue levels of cytokines demon-
strated a statistically significant difference between treat-
ment and controls animals (Table 3). However, focusing
on the proinflammatory cytokines (IL-1a, IL-1b, IL-2,TABLE 2. Flow cytometry results
Flow cytometry antibodies
Control
(n ¼ 6)
Treatment
(n ¼ 6) P value
CD11b/c low (macrophages) 111.6  31.4 85.1  41.6 .54
CD11b high (neutrophils) 139.9  42.9 117.2  50.5 .58
CD3 (all T-cells) 217.3  126.4 159.1  89.6 .65
CD4 (helper T-cells) 392.9  137.5 308.7  117.8 .44
CD8 (cytotoxic T-cells) 173.9  43.4 139.2  52.4 .39
CD4/CD25 (regulatory
T-cells)
63.7  26.3 40.7  12.1 .26
CD3 /gd TCR (gd T-cells) 27.5  10.4 22.4  5.5 .55
Cells/g tissue 60.2  16.5 47.6  16.9 .35
Data are presented as mean  standard deviation3 106/g lung tissue. CD, Clusters of
differentiation; TCR, T-cell receptor.
1216 The Journal of Thoracic and Cardiovascular SurIL-6, and IL-18), a downward trend in the treatment group
versus controls was noted (Table 3). None of the isograft
levels of chemoattractants demonstrated a statistically sig-
nificant difference between treatment group and controls
(Table 3).
DISCUSSION
Donor lung ischemia due to blood-supply interruption at
the time of graft procurement results in the loss of mecha-
notransduction in the capillaries and arterioles of the donor
lung which in turn leads to the generation of reactive oxy-
gen species and cytokines through the activation of donor
macrophages and endothelial cells, priming the donor
lung tissue for injury upon reperfusion. As reperfusion
occurs after implantation of the graft into the recipient, cy-
tokines and reactive oxygen species are released into the
recipient circulation and the entry of activated neutrophils
from the recipient into the donor lung facilitated by upregu-
lated nitric oxide signaling leads to direct vascular damage.
Increased pulmonary vascular resistance and permeability
within the donor lung ensue with the development of the
clinical picture of pulmonary edema, worsening oxygena-
tion, and decreased lung compliance.8,9
A growing body of literature has highlighted common
pathways between IRI and rejection related to the funda-
mentally inflammatory/immune-mediated nature of IRI.
In the setting of transplantation the reperfusion phase of
IRI represents the first contact between the recipient inflam-
matory/immune system and donor tissue damaged by an
ischemic insult, setting the stage for the subsequent devel-
opment of graft rejection. The association of IRI with an
increased risk of acute and chronic rejection may be related
to an increased scope of donor epitope display to the recip-
ient immune system due to cellular injury which results in a
more differentiated and pronounced recipient versus donor
immune response.2,10 A link between IRI and rejection
suggests that immunosuppressive medications may
represent a possible treatment avenue in IRI.
In prior studies, treatment of animals with systemic
immunosuppression before submitting the lung to ischemia
and reperfusion resulted in an attenuation of IRI.4 However,
an important limitation of translating this strategy to human
donors is the risk of nephrotoxicity due to the high systemic
doses of tacrolimus required to achieve therapeutic drug
levels in the lung graft with the potential of compromising
the quality of donor renal allografts. This limitation may be
overcome through the use of inhaled immunosuppressant
therapy in donors; the inhalational route has been shown
to provide high lung levels of immunosuppressant with
low systemic absorption using a nanoparticle drug formula-
tion.5 This has the potential not to interfere with other organ
procurement teams and their organ harvests.
The purpose of this study was to evaluate early changes in
the IRI and the effect of inhaled nanoparticle tacrolimus ongery c November 2013
FIGURE 2. A, Oxygen tension (PO2) level plotted against tacrolimus levels in the lung tissue measures after 3 hours of ischemia. B, Clusters of differen-
tiation (CD)11b high cells (neutrophils) plotted against tacrolimus levels in the lung tissue after 3 hours of ischemia.
Bayer et al Evolving Technology/Basic Sciencethese, therefore 4 hours of reperfusion time point was cho-
sen. The literature supports that within the first few hours af-
ter reperfusion there is an upregulation of cytokine
expression and influx of inflammatory cells into the
lung.7,11-14 In our study numerous inflammatory cytokines
(Table 3) and all examined cellular elements (Table 2)TABLE 3. Results for cytokines and chemoattractants
Variable Control (n ¼ 6) Treatment (n ¼ 6) P value
Cytokines
IL-1a 166.6  107 87.7  33.6 .21
IL-1b 152.4  62.2 95.7  36.6 .16
IL-2 10.8  5.3 8.8  2.8 .8
IL-4 25.9  10.6 22.2  10.1 .81
IL-5 9.1  2.5 11.4  3.7 .61
IL-6 181.7  99.7 112.6  91.3 .26
IL-10 8.1  4.7 5.8  4.2 .42
IL-17A 4.8  0.8 5.2  0 .51
IL-18 480.2  117.5 368.3  103.3 .2
IFN g 9.5  2.1 10.3  0 .51
TNFa 4.1  2.2 2.2  1 .15
Chemoattractants
MIP-1a 140.8  62.8 101.9  30.1 .56
MIP-2 577.3  311.8 568.3  211.8 .93
MCP-1 185.9  89.4 136.9  81 .46
IP-10 41.6  22 31  10 .5
GRO/KC 2094.7  1389.5 1616.8  735.5 .94
Fractalkine 92.7  29.3 79.8  17.3 .7
RANTES 565.6  72.9 578.2  137.7 1.0
Data are presented as mean  standard deviation. IL, Interleukin; IFN, interferon;
TNF, tumor necrosis factor;MIP, macrophage inflammatory protein;MCP, monocyte
chemoattractant protein; IP, interferon gamma–induced protein; GRO/KC, human
growth regulated oncogene/keratinocyte chemoattactant; RANTES, Regulated on
Activation Normal T cell Expressed and Secreted.
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compared to controls, but none were statistically signifi-
cantly different. This may be a limitation of the reperfusion
endpoint chosen in this study. Other studies have suggested
that influx of inflammatory cells progressively increases after
4 hours of reperfusion over the next 24 hours.12 Most of
studies evaluating IRI use a warm ischemia model or longer
ischemia time, which could lead to a greater insult during the
period of ischemia and a greater reperfusion injury. Possibly
by choosing a longer ischemia time a greater ischemic insult
could have been inflicted during this study, leading to a
greater reperfusion injury with increased influx of lympho-
cytes and release of inflammatory cytokines, which could
have lead to show a greater difference in the cellular and
cytokine analysis between treatment and control group.
Even though significant changes in the oxygenation of
the treatment and control group were found, no difference
in the wet to dry ratio between the groups were noted.
The wet to dry ratio is a simple way to gravimetrically
assess pulmonary edema. Limitations of this method are:
blood inclusion and extravasated protein can falsely in-
crease the ratio, evaporative losses and spontaneous respira-
tion versus mechanical ventilation can affect the ratio,
regional heterogeneity of edema cannot be assessed, and
hydrostatic edema and increased vascular permeability
cannot be distinguished.15 In this study this approach was
chosen over other methods to measure pulmonary edema
(eg, permeability index), because this is an easy way to
assess pulmonary edema without sacrificing the majority
of lung tissue making it unavailable for further analyses,
recognizing its limitations. In addition performing bron-
choalveolar lavage during the necropsy might have affecteddiovascular Surgery c Volume 146, Number 5 1217
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therefore affecting the wet to dry weight ratio.
Other studies using a warm ischemia model in rats,
administering tacrolimus either systemically or endotra-
cheally were able to show attenuation of the ischemia reper-
fusion injury with decreased amount of neutrophil
accumulation and inflammatory cytokine production. The
proposed underlying mechanism from these authors was a
reduction of nuclear factor kB activation by tacrolimus.4,16
Main limitation of their study was the use of a warm
ischemia model, in contrast to our study, which used an
orthotopic lung transplant model with cold ischemia,
mimicking the clinical scenario of lung transplantation
more closely. Nuclear factor kB activation is an early
event in the inflammatory cascade of the IRI, which might
not be the only way in which tacrolimus might affect the
IRI. The main mechanism of action for which tacrolimus
is known for, is the IL-2 inhibition.3 In this study a decrease
in IL-2 production was noted in the treatment group
compared with the control group, but this was not signifi-
cant. Further this study did not investigate the mechanism,
through which inhaled tacrolimus affect the IRI, nor did it
look at the long-term effect of tacrolimus on the ischemia
reperfusion injury, but this could be grounds for other
studies in the future.
One main limitation of this study was the small samples
sizes employed. Despite the observation of a significant dif-
ference in oxygenation between treatment and control
groups, the study was not adequately powered to identify
statistically significant differences in cytokine concentra-
tion or inflammatory/immune cell presence in the lung tis-
sue of the 2 cohorts. This limited the conclusions that
could be drawn about the mechanism of action of the
drug in attenuating IRI.
Another important limitation of this study related to the
inhaled drug delivery system employed. Drug delivery to
the distal airways and alveoli required passage across the
upper airways of awake, spontaneously breathing animals,
which undoubtedly led to some drug loss to the upper air-
ways or even externally to the experimental animal. In
two of the six treatment animals this system failed to deliver
sufficient drug to the alveoli, resulting in low isograft tissue
levels of drug, which in turn was associated with decreased
oxygenation and increased neutrophil presence in the
isograft. In human lung donors, these limitations should
theoretically not apply in that all human lung donors are
supported with mechanical ventilation via some sort of
endotracheal airway allowing direct access to the distal air-
ways for more accurate drug delivery. Mc Courtie and col-
leagues17 found in their study assessing ischemia
reperfusion injury in the rat lung, that only high dose sys-
temically administered tacrolimus, but not low-dose tacro-
limus reduced lung injury and activation of nuclear factor
kB. This suggests that a certain threshold of tacrolimus in1218 The Journal of Thoracic and Cardiovascular Surthe lung tissue must be reached for the drug to assert its
beneficial effects on the inflammatory cascade and atten-
uate the ischemia reperfusion injury. It is possibly that the
2 animals in this study with the low tacrolimus levels did
not show an improvement in the ischemia reperfusion injury
because the drug did not reach the required tissue threshold
concentration.
In our study, pretreatment of donor animals with inhaled
nanoparticle tacrolimus before organ procurement and
transplantation into recipient animals significantly attenu-
ated the adverse effects of IRI on isograft gas exchange
with the treatment group demonstrating markedly higher
arterial oxygen tension levels and diminished alveolar-
arterial oxygen gradients compared with controls, as long
as a threshold of drug concentration was reached. This
attenuation of IRI by inhaled nanoparticle tacrolimus ap-
peared to be related directly to the immunosuppressant/
anti-inflammatoty property of tacrolimus in that for treat-
ment animals a consistent decrease in cytokine expression
was observed compared with controls, although no individ-
ual cytokine expression decrease achieved statistical signif-
icance. Additionally, a consistent decrease in the presence
of inflammatory/immune cellular elements in the lung tis-
sue of treatment animals was observed despite not being
statistically significant.CONCLUSIONS
These findings taken as a whole suggest that inhaled
nanoparticle tacrolimus therapy, through a local
immunosuppressive/anti-inflammatory effect, may provide
a means of mitigating IRI in lung transplantation.
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Discussion
Dr Joseph Zwischenberger (Lexington, Ky). Dr Bayer, you are
to be congratulated for such a technically challenging approach to
orthotopic lung transplant as well as the use of nanoparticles. The
issue with nanoparticles is that you have to do the pharmacoki-
netics, you have to match the delivery medium with the drug
you are intending to deliver, and then you have to make sure it
gets to the right place.
I am concerned about a couple things. First of all, you showed a
distinct split between the dose delivery in the 4 rats that seemed to
take on the drug and the 2 that did not. I would like to hear you
comment, first of all, on how they were able to inhale the agent.
You mentioned that they were inhaled, but you did not tell us
how or the circumstances or how you would control the dosimetry.
The second question is, you only used 6 animals in each group,
and because only 4 got the drug, we really did a study on 4 rats.
I am concerned that we did not have a large enough N. Lastly,
we are all judged on lung transplantation at 1-year and 3-year sur-
vivals, and yet this study only went 4 hours.
I would like to hear your responses to those, please.
Dr Bayer. To your first question about the delivery of the drug,
in a pharmacokinetic study that had been done previously, wewere
able to show adequate delivery of the drug to the rats. One of the
problems is that the rat is placed into a nose-only chamber and this
is connected to an Aeroneb nebulizer (Aerogen, Galway, Ireland)
where the medication gets aerosolized and the rat breathes sponta-
neously. Things that could affect the drug delivery are if the rat has
rapid breathing or anxiety, there could be unequal delivery into theThe Journal of Thoracic and Carlungs; some of the drug could be deposited into the main airway
and not go all theway into the lower airways; and if they have rapid
breathing, the drug could be eliminated faster. I think in future
studies we might need to test administering the drug while the
rats are endotracheally intubated and mechanically ventilated
and we might have a more uniform delivery of the drug.
Your question about the N, prior to the study, when we were
doing our proposal, we had a power calculation done by our statis-
tics department. They suggested that an N of 6 should be appro-
priate to see a treatment effect. We did not anticipate that 2 rats
would have lower tacrolimus levels compared with the rest of
them. Now, reviewing our results we might have needed a higher
N in the beginning to show a beneficial effect of the medication.
Dr Zwischenberger. And the 4 hours?
Dr Bayer. We wanted to look at early changes after ischemia-
reperfusion injury. We know that within a few hours after reperfu-
sion that there is already an abundant amount of release of inflam-
matory cytokines and influx of neutrophils, T-cells, and
macrophages into the graft. Other studies that we looked at before
the start of our experiments used a similar reperfusion time of 4
hours and were able to show an effect on the ischemia reperfusion
injury with pretreatment of tacrolimus.
Dr Zwischenberger. So you have hit upon a very important
point and that is that the delivery of nanoparticles is very depen-
dent on how slowly and how deeply the recipient breathes and
how it is delivered. I look forward to when you train your rats to
breathe slow and deep.
Dr Frank D’Ovidio (New York, NY). I have a couple of ques-
tions. What was the preservation solution that you used for the
lungs?
Dr Bayer.We did not preserve the lungs. We used fresh lung for
our flow cytometry analysis, and then the lung was frozen for the
rest of the analysis.
Dr D’Ovidio. No, I mean during the ischemic period of time.
Did you flush the lungs?
Dr Bayer. When the lungs were harvested, we flushed them
with the preservation solution Perfadex (Xvivo, G€oteborg,
Sweden), and then they were stored in an inflated state on ice.
Dr D’Ovidio. I probably missed it throughout the presentation.
Why did you have to use lactose as a vehicle?
Dr Bayer. Lactose was chosen because it is well tolerated,
easily absorbed, and it is thought to help with the absorption of
the tacrolimus, which is by nature a lipophilic drug.
Dr D’Ovidio. Along that line, did you try a group of rats where
you just used normal saline and see what the inflammatory
response is from delivering lactose?
Dr Bayer. I’m sorry, could you please explain your question?
Dr D’Ovidio. Did you test the lactose per se versus a control
group of normal saline?
Dr Bayer. No, we have not done that. That would be something
we could include in a future study.
Dr D’Ovidio. I would suggest you do it, because a 3-hour
ischemic time in a rat model historically would give much better
PO2s, and I wonder if the lactose per se is giving you an inflamma-
tory process. I would double-check for that. I worked with amodel,
and to get the model to work, we would have to implement 18
hours of cold ischemia to show the difference in PO2s.diovascular Surgery c Volume 146, Number 5 1219
